AAP
RIGL icon

Arax Advisory Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Arax Advisory Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.51K Buy
+243
New +$7.5K ﹤0.01% 4359
2026
Q1 		– Sell
-1
Closed -$43 – 4239
2025
Q4 		$43 Sell
1
-249
-100% -$9.39K ﹤0.01% 3943
2025
Q3 		$7.08K Buy
+250
New +$7.48K ﹤0.01% 2739
2025
Q2 		– Sell
-32
Closed -$576 – 3176
2025
Q1 		$576 Sell
32
-53
-62% -$1.07K ﹤0.01% 2520
2024
Q4 		$1.43K Hold
85
– – ﹤0.01% 2089
2024
Q3 		$1.38K Hold
85
– – ﹤0.01% 2161
2024
Q2 		$699 Buy
+85
New +$890 ﹤0.01% 2270

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's RIGL Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 243 shares worth $9.51K. The stake represents ﹤0.01% of the portfolio and ranks #4359 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in RIGL as recently as Q4 2025.

Arax Advisory Partners first reported a position in RIGL in Q2 2024 and has held it in 7 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Arax Advisory Partners held 243 shares of Rigel Pharmaceuticals worth $9.51K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4359 holding.
  • Arax Advisory Partners first reported a position in Rigel Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.